[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Excellent vaccine results, takes time", "description": "BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting\n\nhttps://www.nejm.org/doi/full/10.1056/NEJMoa2101765?query=featured_home\n\nMETHOD\n\nVaccinations, December 20, 2020, to February 1, 2021\n\nMatched to unvaccinated controls in a 1:1 ratio\n\nAccording to demographic and clinical characteristics\n\nN = 596,618 (in each group)\n\nDOCUMENTED INFECTIONS, 10,561 \n\nSymptomatic infections, 5,996 (57%)\n\nRequiring hospitalisation, 369\n\nSevere cases of Covid-19, 229\n\nDeaths, 41\n\nRESULTS\n\nVaccine effectiveness at days 14 through 20 after the first dose\n\nVaccine effectiveness at 7 or more days after the second dose\n\nDocumented infection\n\n46% and 92%\n\nSymptomatic Covid-19\n\n57% and 94% \n\nHospitalization \n\n74% and 87% \n\nLast hospitalisation in the vaccinated group at 32 days\n\nSevere disease\n\n62% and 92% \n\nLast severe case in the vaccinated group at 30 days\n\n\nEffectiveness in preventing death\n\n72% for days 14 through 20 after the first dose \n\nDeaths after 44 days\n\nVaccinated group, 9 \n\nUnvaccinated group, 32 \n\nLast death in the vaccinated group at 30 days\n\nCONCLUSIONS\n\nConsistent with a gradual daily increase in vaccine effectiveness\n\nThis study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19\u2013related outcomes, a finding consistent with that of the randomized trial.", "link": "https://www.youtube.com/watch?v=sNCrzOl2PfA", "date_published": "2021-02-28 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "International trends", "description": "United States\n\nTrends\n\nhttps://covid.cdc.gov/covid-data-tracker/#trends_dailytrendscases\n\nHospitalizations\n\nhttps://covid.cdc.gov/covid-data-tracker/#hospitalizations\n\nFactors in increased cases and deaths (Mike)\n\nWeather, delayed data\n\nVacation week\n\nVirginia and Texas backlog of deaths not reported\n\nVaccine news\n\nJohnson & Johnson, US authorization probably today\n\nCalifornia, expecting 380,000 doses by next week\n\nOne shot\n\nNormal fridge for 3 months\n\nViral vector\n\n66% effective against any case of moderate to severe illness in a large, global trial\n\n85% effective against severe disease\n\nNo hospitalizations or deaths, after 4 weeks\n\nFDA\n\nAllow undiluted frozen vials of Pfizer to be moved at freezer temperatures for \nup to two weeks\n\nCanada\n\nApproves Oxford AstraZeneca vaccine\n\n18 and older\n\n20 million doses advance purchase agreement\n\nSouth Korea\nVaccination started Friday\n\nhttps://www.theguardian.com/world/2021/feb/25/acceptance-problem-as-most-oxford-covid-jabs-delivered-to-eu-not-yet-used\n\nUK\n\nhttps://covid.joinzoe.com/data\n\nhttps://coronavirus.data.gov.uk\nFirst dose: 19,177,555\n\nSecond dose: 736,037", "link": "https://www.youtube.com/watch?v=N-jJwUUhFT8", "date_published": "2021-02-27 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]